Influenza A is NOT an absolute contraindication to repeat TURBT for high-grade urothelial carcinoma, but the procedure should be delayed until the acute infection resolves.
For high-grade non-muscle invasive bladder cancer (NMIBC), repeat TURBT should be performed within 2-6 weeks of initial resection to detect residual disease (present in 20-71% of T1 cases) and upstaging (occurring in up to 25% of cases), which directly impacts mortality and progression-free survival 1, 2. However, active influenza A infection temporarily increases perioperative risks and should prompt a brief delay.
Clinical Decision Algorithm
Assess Disease Urgency
- High-grade Ta or T1 disease: Repeat TURBT is strongly indicated and should not be indefinitely postponed 2
- Timing window: The 2-6 week window is based on level 3 evidence showing longer recurrence- and progression-free survival when performed 14-42 days after initial resection versus 43-90 days 1
- Mortality impact: Studies demonstrate repeat TURBT reduces overall mortality from 26-36% to 22-30% in T1 disease 2
Manage the Influenza Infection
- Delay duration: Postpone repeat TURBT for 7-10 days or until influenza symptoms resolve and fever subsides
- Rationale: Active influenza increases risk of:
Maintain the Critical Timing Window
- If influenza occurs early in the 2-6 week window: Delay by 1-2 weeks still allows completion within the optimal timeframe
- If influenza occurs late (week 5-6): Proceed once patient is afebrile and clinically stable, even if slightly beyond 6 weeks—the oncologic benefit of repeat TURBT outweighs the marginal timing delay
Key Evidence Supporting This Approach
The guidelines are unequivocal about the importance of repeat TURBT for high-grade disease. Residual tumor is found in 17-67% of Ta cases and 20-71% of T1 cases at repeat resection 2. More critically, upstaging to muscle-invasive disease (T2) occurs in 9-15% of cases, fundamentally changing treatment from bladder preservation to radical cystectomy 1.
During the COVID-19 pandemic, the EAU recommended that repeat TURBT could be postponed in highly selected patients after BCG induction, but this was an extraordinary circumstance with specific conditions 6. A short delay for acute influenza is reasonable and does not fall into the same category as indefinite postponement.
Common Pitfalls to Avoid
Do not treat influenza A as an absolute contraindication: Unlike bladder perforation or severe hemorrhage (which are true contraindications to immediate intravesical chemotherapy 1, 7), influenza is a temporary condition
Do not delay beyond 8-10 weeks total: Evidence shows that delays beyond 43-90 days significantly worsen recurrence and progression outcomes 1
Do not confuse this with low-grade disease: For TaG1/low-grade tumors, repeat TURBT is not mandatory even without muscle in the specimen 2, but high-grade disease requires restaging
Ensure antibiotic prophylaxis when proceeding: Given the patient's recent viral infection and potential for secondary bacterial infection, perioperative antibiotics are particularly important 1, 8
Practical Implementation
- Week 0: Initial TURBT shows high-grade disease
- Week 2: Patient develops influenza A
- Week 3: Delay repeat TURBT; treat influenza symptomatically
- Week 4: Once afebrile >48 hours and clinically recovered, proceed with repeat TURBT (still within optimal 2-6 week window)
The oncologic imperative of detecting residual disease and preventing understaging in high-grade NMIBC outweighs a brief delay for acute influenza resolution, but the procedure should not be performed during active febrile illness.